Want to see HK:2196 full AI Analyst Report?

Shanghai Fosun Pharmaceutical (Group) Co (2196) Price & Analysis

5 Followers

2196 Stock Chart & Stats

HK$16.56

HK$0.13(0.81%)

At close: Jul 27 4:00 PM EDT

HK$16.56

HK$0.13(0.81%)

Day’s Range― - ―

52-Week RangeHK$14.90 - HK$29.00

Previous CloseN/A

Volume1.85M

Average Volume (3M)3.67M

Market Cap

HK$64.20B

Enterprise ValueHK$78.25K

Total Cash (Recent Filing)HK$16.31B

Total Debt (Recent Filing)HK$39.45B

Price to Earnings (P/E)17.5

Beta1.13

Next Earnings

Nov 03, 2026

EPS Estimate

0.41

Next Dividend Ex-DateN/A

Dividend Yield2.78%

Share Statistics

EPS (TTM)1.90

Shares Outstanding551,940,500

10 Day Avg. Volume4,769,813

30 Day Avg. Volume3,673,685

Financial Highlights & Ratios

PEG Ratio0.74

Price to Book (P/B)0.95

Price to Sales (P/S)1.15

P/FCF Ratio60.76

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$22.45

Price Target Upside35.57% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)1.44

Revenue Forecast (FY)HK$42.83B

Bulls Say, Bears Say

Bulls Say

Revenue ReboundThe strong TTM revenue rebound indicates improving demand, pricing, or product mix after several weaker years. If sustained, renewed top-line growth can expand the company’s commercial scale, support fixed-cost absorption, and provide a stronger base for investment across its pharmaceutical businesses.

Stable Gross And Net MarginsMaintaining approximately 49% gross margins and 8% net margins demonstrates that Fosun Pharma retains meaningful profitability across its product and service portfolio. This margin base can support continued research, commercialization, and channel investment while providing resilience if revenue growth moderates.

Improving Operating Cash FlowHigher operating cash flow strengthens earnings quality and gives the company internally generated funding for operations, product development, and debt servicing. The increase from 2023 suggests that improved business performance is translating into cash generation, even though conversion remains imperfect.

Bears Say

Rising LeverageThe increase in debt-to-equity shows that expansion is relying more heavily on borrowing while equity remains relatively stable. Higher leverage reduces financial flexibility, increases the importance of dependable cash generation, and can constrain future investment or shareholder-return choices.

Uneven Free Cash FlowAlthough current free cash flow is positive, its decline and history of negative or near-breakeven outcomes indicate inconsistent cash available after investment needs. This variability can limit the company’s ability to fund growth internally and makes higher leverage more burdensome over time.

Lower Operating LeverageA lower EBIT margin than the 2024 peak suggests that revenue improvement is not translating into the same level of operating leverage. Persistent cost pressure could limit profit growth, weaken the benefit of future sales expansion, and make earnings more sensitive to product mix and execution.

Shanghai Fosun Pharmaceutical (Group) Co News

Fosun Pharma Launches Up to HK$1 Billion H-Share Buyback Plan

An announcement from Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) is now available. Shanghai Fosun Pharmaceutical has...

1d ago

Fosun Pharma Wins China Approval for New Luvometinib Indication

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has shared an announcement. Shanghai Fosun Pharmaceutical said its subsidiary,...

4d ago

Fosun Pharma Grants Reserved A Share Options Under 2025 Incentive Scheme

An announcement from Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) is now available. Shanghai Fosun Pharmaceutical has...

10d ago

Fosun Pharma Grants New H Share RSUs to 100 Employees Under 2025 Incentive Scheme

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has issued an announcement. Shanghai Fosun Pharmaceutical has approved a...

10d ago

Fosun Pharma Unit Secures Exclusive Rights to Advanced Bispecific Antibody Drug

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has provided an announcement. Shanghai Fosun Pharmaceutical has announced that...

11d ago

Shanghai Fosun Pharma Executes HK$3.6 Million H-Share Buyback

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has shared an update. Shanghai Fosun Pharmaceutical (Group) Co., Ltd....

11d ago

Fosun Pharma Posts Modest Profit Growth in First-Half 2026 Results

The latest announcement is out from Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ). Shanghai Fosun Pharmaceutical (Group)...

13d ago

Shanghai Fosun Pharmaceutical (Group) Co Class H (SFOSF) Q2 Earnings Cheat Sheet

Shanghai Fosun Pharmaceutical (Group) Co Class H (SFOSF) is scheduled to report 2nd quarter earnings on 08/25/2026. Regarding...

15d ago

Fosun Pharma Subsidiary Advances COPD Drug FXS7553 Into Phase II Trial in China

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has issued an announcement. Shanghai Fosun Pharmaceutical has announced that...

25d ago

Fosun Pharma Sets August Board Meeting to Approve 2026 Interim Results

Shanghai Fosun Pharmaceutical (Group) Co ( ($HK:2196) ) has issued an announcement. Shanghai Fosun Pharmaceutical (Group) Co., Ltd....

25d ago

Shanghai Fosun downgraded to Hold from Buy at HSBC

HSBC downgraded Shanghai Fosun to Hold from Buy with a price target of HK$20, down from HK$40. The...

3y ago

Syneos Health partners with Fosun Pharma USA to launch serplulimab

Syneos Health (SYNH) announced a strategic partnership with Fosun Pharma USA (SFOSF). As part of the partnership, Syneos...

4y ago

SYNH

2196 FAQ

What was Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price range in the past 12 months?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H lowest stock price was HK$14.90 and its highest was HK$29.00 in the past 12 months.

What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap is HK$64.20B.

When is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date is Nov 03, 2026 which is in 57 days.

How were Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s earnings last quarter?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H released its earnings results on Aug 25, 2026. The company reported HK$0.373 earnings per share for the quarter, missing the consensus estimate of HK$0.42 by -HK$0.047.

Is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H overvalued?

According to Wall Street analysts Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pay dividends?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pays a Annually dividend of HK$0.45 which represents an annual dividend yield of 2.78%. See more information on Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H dividends here

What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate is 0.41.

How many shares outstanding does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H have?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H has 551,940,500 shares outstanding.

What happened to Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price movement after its last earnings report?

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H reported an EPS of HK$0.373 in its last earnings report, missing expectations of HK$0.42. Following the earnings report the stock price went up 3.036%.

Which hedge fund is a major shareholder of Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H?

Currently, no hedge funds are holding shares in HK:2196

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Shanghai Fosun Pharmaceutical (Group) Co Stock Smart Score

Neutral

Fundamentals

Return on Equity

2.78%

Trailing 12-Months

Asset Growth

11.60%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive healthcare enterprise, operating across Mainland China and international markets. Its principal activities include the research, development, production, and commercialization of pharmaceutical products. The company focuses on significant therapeutic domains such as oncology, immunology, metabolic disorders, gastrointestinal health, and central nervous system conditions. In addition to its drug offerings, Fosun Pharma provides medical devices and diagnostic solutions. Its multifaceted operations are organized into five key segments: pharmaceutical manufacturing, medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail, and other business initiatives. This scope extends to managing healthcare facilities and hospitals, as well as the wholesale and retail distribution of medicines. The company was founded in 1994 and is headquartered in Shanghai, China.

Shanghai Fosun Pharmaceutical (Group) Co (2196) Earnings & Revenues

Historic Earnings Reports

2196 Stock 12 Month Forecast

Average Price Target

HK$22.45

▲(35.57% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"HK$13","20":"HK$20","27":"HK$27","16.5":"HK$16.5","23.5":"HK$23.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":26.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$26.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.450000000000003,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$22.45</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$18.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,16.5,20,23.5,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.11,16.916923076923077,17.723846153846154,18.53076923076923,19.337692307692308,20.144615384615385,20.951538461538462,21.75846153846154,22.565384615384616,23.372307692307693,24.17923076923077,24.986153846153847,25.793076923076924,{"y":26.6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.11,16.597692307692306,17.085384615384616,17.573076923076922,18.060769230769232,18.548461538461538,19.036153846153848,19.523846153846154,20.011538461538464,20.49923076923077,20.98692307692308,21.474615384615387,21.962307692307697,{"y":22.450000000000003,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.11,16.27846153846154,16.446923076923078,16.615384615384617,16.783846153846152,16.95230769230769,17.12076923076923,17.28923076923077,17.45769230769231,17.626153846153848,17.794615384615383,17.963076923076922,18.13153846153846,{"y":18.3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.247,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.097,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.189,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.813,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.032,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.343,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.827,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.918,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.603,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.695,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.709,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.42,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.11,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >